Meeting
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
Authors
Lorenzo Falchi
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Lorenzo Falchi , Fritz Offner , David Belada , Joshua Brody , Kim M. Linton , Yasmin Karimi , Raul Cordoba , Sylvia Snauwaert , Aqeel Abbas , Liwei Wang , Jun Wu , Brian Elliott , Michael Roost Clausen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT04663347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7523)
DOI
10.1200/JCO.2022.40.16_suppl.7523
Abstract #
7523
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2023 ASCO Annual Meeting
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data.
First Author: Lorenzo Falchi
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.
First Author: He Huang
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin